Recombinant adenovirus with removed EZA gene and method of prepa

Details Recombinant adenovirus with removed EZA gene and method of prepa Recombinant adenovirus with removed EZA gene and method of prepa

1996-03-12

1997-12-23

Knode, Marian C.

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

4241991, 4353201, 43525232, 514 44, 536 2372, 935 22, 935 23, 935 52, A61K 3923, A61K 3912, C12N 1500, C12N 120

Patent

active

057004706

ABSTRACT:
A recombinant DNA virus for transfecting an animal cell and bearing a foreign gene and a promoter capable of regulating expression of the foreign gene is completely deleted of the function of E2A gene. The recombinant DNA virus can thus stably transduce the foreign gene into various animal cells, which leads to continuous expression of the foreign gene in the animal cells. The continuous expression of the foreign gene can provide an effective treatment of hereditary disease.

REFERENCES:
Sauer, B. et al, 1988, PNAS, vol. 85, pp. 5166-5170.
Niwa et al., "Efficient Selection for High-Expression Transfectants with a Novel Eukaryotic Vector," Gene, 108, pp. 193-200 (1991).
Engelhardt et al., "Direct Gene Transfer of Human CFTR Into Human Bronchial Epithelia of Xenografts with El-Deleted Adenoviruses," Nature Genetics, vol. 4, pp. 27-34 (May 1993).
Saito et al., "Adenovirus Vector," the 41st General Meeting: The Society of Japanese Virologists (1993).
Kanegae et al., "Adenovirus Vector and Gene Therapy," Experimental Medicine, vol. 12, No. 3 (1994).
Kanegae et al., Experimental Medicine Supplemental Volume, Biomanual Series 4, pp. 43-58 (1994).
Gu et al., "Deletion of DNA Polymerase . . . Targeting," Science, vol. 265, Jul. 1, 1994, pp. 103-106.
Anton et al., "Site Specific Recombinaiton Mediated . . . Expression," Journal of Virology, Aug. 1995, pp. 4600-4606.
First Annual Meeting 1995 Japanese Society of Gene Therapy, Program and Abstract, May 21, 1995, Kanagae et al, "Application of Cre/LoxP System to Adenovirus Vector".
Kanegae et al., "Efficient Gene Activation . . . Recombinase," Nucleic Acids Research, vol. 23, No. 19, pp. 3816-3821 (1995).
Bergemann et al., "Excision of Specific DNA . . . Recombination, " Nucleic Acids Research, vol. 23, No. 21, pp. 4451-4456 (1995).
The 43rd Annual Meeting of the Society of Japanese Virologists, (Sep. 29, 1995), 2016, p. 126.
The Second Brain Tumor Gene Therapy Meeting, Feb. 3 and 4, 1995, "Adenovirus Vector".
Engelhardt et al, "Ablation of E2A in recombinant adenoviruses improvesd transgene persistence . . . ," Proc. Natl. Acad. Sci., vol. 91, pp. 6196-6200, Jun. 1994.
Yang et al, "Inactivation of E2A in recombinant adenoviruses improves the prospects for gene therapy in cystic fibrosis," Nature Genetics, vol. 7, pp. 362-369, Jul. 1994.
Gorziglia et al, "Elimination of both E1 and E2a from Adenovirus Vectors Further Improves Prospects for In Vivo Human Gene Therapy," J. Virology, vol. 70, No. 6, pp. 4173-4178, Jun. 1996.

Affiliated with

Also associated with

Rating

Recombinant adenovirus with removed EZA gene and method of prepa does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinant adenovirus with removed EZA gene and method of prepa, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant adenovirus with removed EZA gene and method of prepa will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1800500